Cardiovascular and mortality benefits of sodium–glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus: CVD-Real Catalonia
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cardiovascular and mortality benefits of sodium–glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus: CVD-Real Catalonia
Authors
Keywords
-
Journal
Cardiovascular Diabetology
Volume 20, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-07-10
DOI
10.1186/s12933-021-01323-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effects of sodium‐glucose cotransporter type 2 inhibitors on cardiovascular, renal, and safety outcomes in patients with cardiovascular disease: a meta‐analysis of randomized controlled trials
- (2021) Caiyun Zheng et al. Cardiovascular Diabetology
- Comparative efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) for cardiovascular outcomes in type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials
- (2020) Tobias Täger et al. HEART FAILURE REVIEWS
- Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: Scandinavian cohort study
- (2020) Björn Pasternak et al. BMJ-British Medical Journal
- Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study
- (2020) Shun Kohsaka et al. Lancet Diabetes & Endocrinology
- Dapagliflozin in Patients with Chronic Kidney Disease
- (2020) Hiddo J.L. Heerspink et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dapagliflozin and Cardiovascular Mortality and Disease Outcomes in Type 2 Diabetes Patients Similar to the DECLARE-TIMI 58 Participants: A Nationwide Observational Study
- (2019) Anna Norhammar et al. DIABETES OBESITY & METABOLISM
- The Mediterranean Diet and Cardiovascular Health
- (2019) Miguel A. Martínez-González et al. CIRCULATION RESEARCH
- Meta-analyses of the effects of DPP-4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and hospitalization for heart failure
- (2019) Binayak Sinha et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care
- (2019) Elisabetta Patorno et al. CIRCULATION
- Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial
- (2019) Ofri Mosenzon et al. Lancet Diabetes & Endocrinology
- A Traditional Mediterranean Diet Effectively Reduces Inflammation and Improves Cardiovascular Health
- (2019) Cristina Razquin et al. Nutrients
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020
- (2019) DIABETES CARE
- Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study
- (2019) Hiddo J L Heerspink et al. Lancet Diabetes & Endocrinology
- A Multinational Real-World Study on the Clinical Characteristics of Patients with Type 2 Diabetes Initiating Dapagliflozin in Southern Europe
- (2019) Gian Paolo Fadini et al. Diabetes Therapy
- Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017
- (2018) Thomas R. Einarson et al. Cardiovascular Diabetology
- Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: Results from the CVD-REAL study
- (2018) Mikhail Kosiborod et al. DIABETES OBESITY & METABOLISM
- Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes
- (2018) Sean L. Zheng et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs
- (2018) Mikhail Kosiborod et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Effectiveness of dapagliflozin versus comparators on renal endpoints in the real world: A multicentre retrospective study
- (2018) Gian Paolo Fadini et al. DIABETES OBESITY & METABOLISM
- Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2018) Melanie J. Davies et al. DIABETOLOGIA
- SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- (2018) Thomas A Zelniker et al. LANCET
- Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA-REG OUTCOME® trial
- (2018) Takashi Kadowaki et al. Journal of Diabetes Investigation
- Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry
- (2017) Ovidiu Chioncel et al. EUROPEAN JOURNAL OF HEART FAILURE
- All-Cause Mortality in Patients With Diabetes Under Treatment With Dapagliflozin: A Population-Based, Open-Cohort Study in The Health Improvement Network Database
- (2017) Konstantinos A. Toulis et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis
- (2017) Kåre I Birkeland et al. Lancet Diabetes & Endocrinology
- Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 Inhibitor
- (2017) Jacob A. Udell et al. CIRCULATION
- Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials
- (2016) Matteo Monami et al. ACTA DIABETOLOGICA
- Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis
- (2016) Christian Sonesson et al. Cardiovascular Diabetology
- Prevalent new-user cohort designs for comparative drug effect studies by time-conditional propensity scores
- (2016) Samy Suissa et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis
- (2016) Jason H Y Wu et al. Lancet Diabetes & Endocrinology
- Impact of Diabetes Mellitus on Hospitalization for Heart Failure, Cardiovascular Events, and DeathCLINICAL PERSPECTIVE
- (2015) Matthew A. Cavender et al. CIRCULATION
- Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease
- (2015) André J. Scheen CLINICAL PHARMACOKINETICS
- A comprehensive meta-analysis on evidence of Mediterranean diet and cardiovascular disease: Are individual components equal?
- (2015) Giuseppe Grosso et al. CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION
- Excess Mortality among Persons with Type 2 Diabetes
- (2015) Mauro Tancredi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1·9 million people
- (2015) Anoop Dinesh Shah et al. Lancet Diabetes & Endocrinology
- Glucuretic effects and renal safety of dapagliflozin in patients with type 2 diabetes
- (2015) Deborah Hinnen Therapeutic Advances in Endocrinology and Metabolism
- Two-year outcome of patients after a first hospitalization for heart failure: A national observational study
- (2014) Philippe Tuppin et al. Archives of Cardiovascular Diseases
- Diabetes in Europe: An update
- (2013) T. Tamayo et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
- (2013) Benjamin M. Scirica et al. NEW ENGLAND JOURNAL OF MEDICINE
- Base de datos SIDIAP: la historia clínica informatizada de Atención Primaria como fuente de información para la investigación epidemiológica
- (2012) Bonaventura Bolíbar et al. MEDICINA CLINICA
- Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies
- (2010) The Emerging Risk Factors Collaboration LANCET
- Construcción de un índice de privación a partir de datos censales en grandes ciudades españolas (Proyecto MEDEA)
- (2008) M. Felícitas Domínguez-Berjón et al. Gaceta Sanitaria
- Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Intensive Glucose Lowering in Type 2 Diabetes
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now